Mark Rothera - Mar 12, 2024 Form 4 Insider Report for Viracta Therapeutics, Inc. (VIRX)

Signature
Daniel Chevallard, as Attorney-in-Fact
Stock symbol
VIRX
Transactions as of
Mar 12, 2024
Transactions value $
$0
Form type
4
Date filed
3/13/2024, 08:36 PM
Previous filing
Dec 4, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIRX Stock Option (Right to Buy) Award $0 +475K $0.00 475K Mar 12, 2024 Common Stock 475K $0.99 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/48th of the total shares subject to the Option will vest each month on the same day of the month as the Vesting Commencement Date (as defined below), and if there is no corresponding day, the last day of the month, subject to the Reporting Person continuing to be a Service Provider in accordance with the Company's 2021 Equity Incentive Plan through each such date. The Vesting Commencement Date is January 1, 2024.